Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Meet Xiaomian (02408.HK) repurchased 107,000 shares on October 28 for HK$405,700.
28/10/2026
Zhitong Finance APP News, Xiaomian Meet (02408.HK) announced that on October 28, 2026, it spent HK$405,700 to repurchase 107,000 shares.
Latest
3 m ago
Weihua New Materials (603310.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 37.06 million yuan, a year-on-year decrease of 65.86%.
5 m ago
Xinxiang Chemical Fiber (000949.SZ) released its first three quarters results, with net profit attributable to shareholders of RMB 547 million, up 310.86% year on year.
6 m ago
Tahe Intelligent (603656.SH) released its performance for the first three quarters, with net profit attributable to the parent company of 30.6 million yuan, a year-on-year increase of 6.33%.
7 m ago
Yuanxin Industry (301053.SZ) released its first three quarters performance, with net profit attributable to the parent company of 31.0032 million yuan, a year-on-year increase of 110.73%.
9 m ago
Junshi Biosciences (01877.HK): The marketing application for a new indication of toripalimab injection (subcutaneous injection) for first-line treatment of HER2-expressing urothelial carcinoma has been accepted.
See all latest